Ventyx Biosciences (VTYX) to Release Earnings on Thursday

Ventyx Biosciences (NASDAQ:VTYX) is projected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Ventyx Biosciences to post earnings of ($0.44) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.07. On average, analysts expect Ventyx Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ventyx Biosciences Stock Down 3.5%

VTYX opened at $8.23 on Tuesday. The stock has a market cap of $586.88 million, a PE ratio of -4.90 and a beta of 1.21. The company has a fifty day moving average of $3.70 and a 200-day moving average of $2.71. Ventyx Biosciences has a twelve month low of $0.78 and a twelve month high of $9.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Hudson Bay Capital Management LP bought a new position in shares of Ventyx Biosciences in the second quarter valued at $34,000. Engineers Gate Manager LP bought a new position in shares of Ventyx Biosciences during the second quarter valued at about $42,000. Jump Financial LLC bought a new position in shares of Ventyx Biosciences during the second quarter valued at about $53,000. Ameriprise Financial Inc. bought a new position in shares of Ventyx Biosciences during the second quarter valued at about $60,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Ventyx Biosciences by 337.1% during the second quarter. Tower Research Capital LLC TRC now owns 36,834 shares of the company’s stock valued at $79,000 after purchasing an additional 28,407 shares in the last quarter. 97.88% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on VTYX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Oppenheimer raised their price target on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. Finally, Wall Street Zen upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.